RSL3: Benchmark GPX4 Inhibitor for Ferroptosis Induction in Cancer Research

Executive Summary: RSL3 is a highly selective glutathione peroxidase 4 (GPX4) inhibitor used to induce ferroptosis in cancer cells at nanomolar concentrations (bioRxiv, https://doi.org/10.1101/2024.12.09.627542). RSL3 acts through GPX4 inhibition, leading to lipid peroxidation and non-apoptotic, iron-dependent cell death. In vivo, RSL3 significantly reduces RAS-driven tumor growth without observable toxicity up to 400 mg/kg. The compound is insoluble in water/ethanol, but dissolves effectively in DMSO at ≥125.4 mg/mL. APExBIO provides RSL3 (SKU B6095) for reproducible ferroptosis and redox studies (https://www.apexbt.com/rsl3.html).

Biological Rationale

Ferroptosis is a regulated, iron-dependent form of non-apoptotic cell death characterized by accumulation of lipid peroxides and reactive oxygen species (ROS) (bioRxiv). GPX4 is a selenoenzyme essential for reducing lipid hydroperoxides and maintaining membrane integrity. Inhibition of GPX4 disables the cell's primary defense against lipid peroxidation, leading to ferroptotic cell death. RSL3 specifically targets GPX4, enabling researchers to dissect the ferroptosis signaling pathway, understand redox vulnerabilities in cancer cells, and study the synthetic lethality of oncogenic RAS mutations with ferroptosis inducers.

Mechanism of Action of RSL3 (glutathione peroxidase 4 inhibitor)

RSL3 covalently binds to the active site selenocysteine of GPX4, irreversibly inhibiting its peroxidase activity (bioRxiv). This inhibition leads to accumulation of lipid ROS. The resulting lipid peroxidation triggers ferroptosis, which is distinct from apoptosis, necrosis, and autophagy. RSL3-induced cell death is caspase-independent, iron-dependent, and cannot be rescued by classical apoptosis inhibitors, but can be mitigated by iron chelators or GPX4 overexpression. The process is highly specific: RSL3 does not inhibit other peroxidases under standard conditions. RSL3 is effective at sub-micromolar (low ng/mL) concentrations, particularly in cells harboring oncogenic RAS mutations.

Evidence & Benchmarks

• RSL3 induces ferroptosis by inhibiting GPX4 activity and promoting lethal lipid peroxidation in mammalian cells (bioRxiv).
• In RAS-driven tumor models (e.g., BJeLR xenografts in athymic nude mice), subcutaneous RSL3 administration (≤400 mg/kg) reduces tumor volume significantly without overt toxicity (bioRxiv).
• RSL3 acts with synthetic lethality in the context of oncogenic RAS, selectively sensitizing RAS-mutant cancer cells to ferroptosis (bioRxiv).
• RSL3's cell-killing effect is iron- and ROS-dependent, and can be rescued by iron chelators or antioxidants, but not by caspase inhibitors (bioRxiv).
• At 37°C, RSL3 is soluble in DMSO at concentrations ≥125.4 mg/mL, but insoluble in water or ethanol (APExBIO product page).

Applications, Limits & Misconceptions

RSL3 is widely used to probe ferroptosis mechanisms, screen for redox vulnerabilities, and study RAS-driven cancer cell death. It is also applied in oxidative stress assays and for validating the specificity of ferroptosis inducers. For detailed workflow optimization in oxidative stress assays using RSL3, see this scenario-driven guide, which this article extends by providing recent in vivo benchmarks and mechanistic clarifications. For advanced protocol strategies and troubleshooting, this guide offers complementary practical insights; our current article updates it with new efficacy and toxicity data. In-depth mechanistic discussions of iron-dependent cell death and redox signaling are provided in this article, while the present review clarifies RSL3's selectivity and synthetic lethality profile in RAS-mutant systems.

Common Pitfalls or Misconceptions

• RSL3 does not induce apoptosis or necroptosis; cell death is strictly ferroptotic and iron-dependent.
• Solubility issues arise if DMSO is not used; RSL3 is insoluble in water and ethanol under standard laboratory conditions.
• Overexpression of GPX4 or use of iron chelators can rescue cells from RSL3-induced death, demonstrating pathway specificity.
• Toxicity profiles are model/system dependent; doses up to 400 mg/kg in mice showed no overt toxicity but require careful translation to other species.
• Classical apoptosis inhibitors (e.g., caspase inhibitors) do not mitigate RSL3-induced cell death, which can lead to misinterpretation if not properly controlled.

Workflow Integration & Parameters

For experimental use, RSL3 (SKU B6095) from APExBIO is supplied as a solid and should be stored at -20°C. Prepare fresh DMSO solutions (≥125.4 mg/mL) prior to use; warming and sonication can improve solubility. Typical working concentrations in cell-based assays are in the low nanomolar to micromolar range. Avoid aqueous or ethanol solvents to prevent precipitation. In vivo, RSL3 was administered subcutaneously up to 400 mg/kg in mouse models with no observable toxicity (bioRxiv). For detailed assay optimization and troubleshooting, refer to this evidence-based guidance, which our article builds upon by integrating latest in vivo safety and selectivity data. For product specifications and ordering, see the RSL3 (glutathione peroxidase 4 inhibitor) product page.

Conclusion & Outlook

RSL3 is a benchmark tool for inducing and studying ferroptosis, especially in redox and cancer biology research. Its selectivity for GPX4, robust in vivo performance, and established safety at preclinical doses make it indispensable for dissecting iron-dependent cell death pathways and targeting redox vulnerabilities in cancer. As the field advances, RSL3 will remain critical for understanding ferroptosis and for the rational design of combination therapies targeting synthetic lethality in oncogenic RAS-driven tumors (bioRxiv).